TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35167583
Drug: Active PBM
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PBM combined with intralesional administration of corticoid (IAC)
Study: 35167583
Drug: Sham PBM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham PBM with intralesional administration of corticoid (IAC)
Study: 33938690
Drug: Poly-L-Lactic acid
Normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-L-Lactic acid (PLLA) injections combined with subcision
Study: 33938690
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections combined with subcision (control group)
Study: 33568610
Drug: Topical curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical curcumin
Study: 33568610
Drug: Topical triamcinolone
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triamcinolone acetonide
Study: 32701836
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 mg, BID)
Study: 33625721
Drug: Sitagliptin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin treatment
Study: 33992687
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide nasal spray (NONS)
Study: 34936174
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy Group Intervention targeting Repetitive Negative Thinking (RNT-G)
Study: 33910614
Drug: ARBOX (390
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARBOX (390 mg) administered as 2 capsules per day for 14 days
Study: 33910614
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 14 days
Study: 35809896
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) combined with post-induction chemotherapy
Study: 35924803
Drug: Fentanyl 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.5 μg/kg
Study: 35924803
Drug: Fentanyl 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.0 μg/kg
Study: 32370774
Drug: Pillbox-enabled self-administered
Normalized name: Enablex
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pillbox-enabled self-administered therapy (SAT) with HRZE fixed-dose combination therapy for 15 days
Study: 32370774
Drug: Standard directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard directly observed therapy (DOT)
Study: 32370774
Drug: Pillbox-enabled self-administered
Normalized name: Enablex
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pillbox-enabled self-administered therapy (SAT)
Study: 33452200
Drug: Instantaneous wave-free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instantaneous wave-free ratio guided treatment of non-culprit lesions during the index procedure
Study: 33788485
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (thumbtack needling + external treatment)
Study: 33788485
Drug: External treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: External treatment (shangshi zhitong plaster)
Study: 35648044
Drug: Kikyo-to (Kt)
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kikyo-to (Kt) 2500 mg
Study: 35648044
Drug: Placebo (lactose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose) 2500 mg
Study: 33892754
Drug: Robotic gait
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic gait training targeting paretic propulsion (ten 60‐min sessions, five weeks, twice a week)
Study: 35144699
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO, 5.2 g/d n‐3PUFA)
Study: 33482387
Drug: VOM ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VOM ethanol infusion combined with catheter ablation (CA)
Study: 33482387
Drug: VOM ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VOM ethanol infusion combined with CA
Study: 34590746
Drug: Once-daily omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily omeprazole (1 mg/kg)
Study: 33038502
Drug: Lanifibranor (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanifibranor (800 and 1200 mg/day)
Study: 32083990
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 intravenously plus oral capecitabine 825 mg/m2 two times per day for 14 days every 3 weeks for 6 cycles (DC)
Study: 35008008
Drug: SCIG 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIG 20% biweekly (dose adjustment factor 1.0 or 1.37)
Study: 35008008
Drug: SCIG 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIG 20% weekly and biweekly
Study: 34476095
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K supplementation (menaquinone-7, 360 µg daily)
Study: 34473544
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg once every 2 weeks)
Study: 34473544
Drug: Gemcitabine (GEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (GEM 1000 mg/m2 for 30 minutes on days 1, 8, and 15) or Pegylated Liposomal Doxorubicin (PLD 50 mg/m2 once every 4 weeks)
Study: 33741048
Drug: Order set
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Order set change and facilitation training (2-day workshop with antibiotic stewardship teams)
Study: 32937045
Drug: Belimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (10 mg/kg body weight) plus standard therapy
Study: 33597056
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g wheat protein (WHEAT)
Study: 33597056
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g blend of 15 g wheat plus 15 g milk protein (WHEAT+MILK)
Study: 35419083
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT enterography (CTE) based on modified guided image filtering (GIF) algorithm
Study: 34428740
Drug: Non-Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Metformin
Study: 35644335
Drug: Prophylactic anticoagulation
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anticoagulation therapy delay
Study: 32893536
Drug: Jinye Baidu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinye Baidu Granules, 10 g/time, three times a day for 5 days
Study: 32893536
Drug: Compound Shuanghua
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Shuanghua Granules placebo, 6 g/time, four times a day for 5 days
Study: 32893536
Drug: Compound Shuanghua
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Shuanghua Granules
Study: 33485608
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Depo-Provera (n = 24)
Study: 33485608
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Depo-Provera (n = 9)
Study: 33485608
Drug: Depo-SubQ Provera
Normalized name: depo-subQ provera
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-SubQ Provera 104 (two injections, n = 9)
Study: 36357289
Drug: Comparative probe
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative probe (asking participants to compare which vaccine to take)
Study: 36357289
Drug: Deliberative probe
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deliberative probe (asking participants whether they would like to take the vaccine)
Study: 32472836
Drug: Amber light
Normalized name: amber
DrugBank: Amber (DB14326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amber light therapy
Study: 34802879
Drug: Platinum combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum combination chemotherapy plus pembrolizumab
Study: 34802879
Drug: Platinum combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum combination chemotherapy plus nivolumab and ipilimumab
Study: 37942277
Drug: tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 10 mg twice daily
Study: 35522626
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention for GPs including a workshop on appropriate prescribing of BZDs, tapering-off long-term BZD use, monthly BZD prescription feedback, and access to a support web page.
Study: 36075233
Drug: VLA2001 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLA2001 (0.5 mL; 33 antigen units per dose)
Study: 36075233
Drug: ChAdOx1-S (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1-S (0.5 mL; 2.5 x 10^8 infectious units per dose)
Study: 32160504
Drug: US-guided subacromial
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided subacromial corticosteroid and LA injection
Study: 32160504
Drug: Blind subacromial
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind subacromial corticosteroid and LA injection
Study: 35395383
Drug: Baseline muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline muscle or adipose tissue parameters during 12 weeks of treatment.
Study: 32027441
Drug: Antibiotics (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (280 patients)
Study: 32027441
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (138 patients)
Study: 33895032
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment for patellar fractures; 23 cases treated nonoperatively.
Study: 33895032
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment for patellar fractures; 9 cases treated operatively.
Study: 33895032
Drug: Complications after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complications after treatment for patellar fractures.
Study: 33895032
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment results based on treatment method and fracture type.
Study: 34350055
Drug: Toe clearance
Normalized name: Fungi-Nail Toe and Foot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toe clearance rehabilitative slippers (top-weighted with a lead bead of 200, 300, or 400 g), worn for 10-20 min, 1-3 days/week for 12 months.
Study: 32583931
Drug: 10,000 lux
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 lux bright light therapy (BLT) for 30 minutes in the morning for 14 consecutive days
Study: 32583931
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light bright light therapy (BLT) for 30 minutes in the morning for 14 consecutive days
Study: 32583931
Drug: No bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bright light therapy (no-BLT)
Study: 35805529
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity program and high-protein supplementation (1.3 g/kg BW/day)
Study: 35805529
Drug: High-protein supplementation
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein supplementation (1.3 g/kg BW/day)
Study: 35805529
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily routine)
Study: 33238991
Drug: eASCs (Cx611)
Normalized name: EACS
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eASCs (Cx611) administered intravenously at a dose of 160 million cells (2 million cells/mL, total volume 80 mL) on Day 1 and Day 3
Study: 33238991
Drug: Placebo (Ringer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Ringer Lactate) administered intravenously at the same quantity (total volume of 80 mL) and schedule as the active treatment
Study: 34433306
Drug: Cognitive assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive assessment after randomization but before assigned treatment, using a cognitive battery developed in the REGARDS Study.
Study: 35633025
Drug: Galcanezumab 300
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab 300 mg subcutaneously once a month
Study: 35022943
Drug: Enhanced community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced community treatment (ECT)
Study: 32303210
Drug: Oral nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nystatin (1 ml three times a day)
Study: 32303210
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water (1 ml three times a day)
Study: 34636112
Drug: Eptacog beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptacog beta (EB) at doses of 75 or 225 μg/kg for bleeding episodes and 75 μg/kg or 200 μg/kg for perioperative care.
Study: 34636112
Drug: Eptacog beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptacog beta (EB) for perioperative care (75 μg/kg for minor procedures, 200 μg/kg for major surgeries).
Study: 34071782
Drug: Online health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online health application supported by a mobile telephone or tablet (mHealth)
Study: 2010124724
Drug: parecoxib-sodium 40
Normalized name: parecoxib sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: parecoxib-sodium 40 mg intravenously after operation
Study: 35016998
Drug: Raspberry consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raspberry consumption (280 g/d for 8 weeks)
Study: 32272517
Drug: INhance Post‐Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: INhance Post‐Injection Serum with TriHex Technology®
Study: 33546039
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment
Study: 34551918
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release metformin 3 g daily
Study: 32602557
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (group A)
Study: 32602557
Drug: No physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No physical therapy (group B)
Study: 34736525
Drug: Intensive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive management (treatment to induce remission)
Study: 32391894
Drug: Disney movies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disney movies during chemotherapy
Study: 36401084
Drug: ACE Inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE Inhibitors (ACEi)
Study: 36401084
Drug: Angiotensin Receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin Receptor Blockers (ARB)
Study: 34416898
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of cell-free stem cell-derived extract (CCM)
Study: 32926395
Drug: MTX treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX treatment
Study: 35382631
Drug: Flaxseed (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (30 g/day) for 12 weeks
Study: 34670754
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention with additional milk, yoghurt, and cheese providing 562 (166) mg/day calcium and 12 (6) g/day protein, achieving a total intake of 1142 (353) mg calcium/day and 69 (15) g/day protein (1.1 g/kg body weight)
Study: 35068330
Drug: Krocina™ (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krocina™ (15 mg twice a day for six weeks)
Study: 35708696
Drug: Enzalutamide monotherapy
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide monotherapy (160 mg for 1 year)
Study: 32663998
Drug: Adjunctive Internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Internet intervention (Deprexis)
Study: 32446260
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (17-OH-progesterone treatment without cerclage)
Study: 32484534
Drug: CRP-guided antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP-guided antibiotic treatment duration (n=170)
Study: 32484534
Drug: 7-day fixed
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day fixed antibiotic treatment duration (n=169)
Study: 32484534
Drug: 14-day fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day fixed antibiotic treatment duration (n=165)
Study: 34348323
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray for 3 weeks followed by surgical intervention for 3 months
Study: 34348323
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray for 3 weeks followed by medical management for 3 months
Study: 32456874
Drug: Ofloxacin otic
Normalized name: ofloxacin otic
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin otic solution
Study: 35644957
Drug: Mivacurium (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (0.25 mg/kg injected and continuously infused at 0.3 mg·kg‐1·h‐1)
Study: 35644957
Drug: Cisatracurium besylate
Normalized name: Cisatracurium Besylate
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium besylate (0.1 mg/kg injected, normal saline infused)
Study: 32549996
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus with additional three‐monthly magnetic resonance imaging until remission up to 12 months
Study: 34936269
Drug: Baixiao moxibustion
Normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baixiao moxibustion and qiangshen shugan qiwei decoction (one dose daily)
Study: 34936269
Drug: qiangshen shugan
Approvals — FDA: no, EMA: no, PMDA: no
Description: qiangshen shugan qiwei decoction (one dose daily)
Study: 33229930
Drug: Lidocaine group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine group: perioperative intravenous lidocaine infusion, plus PCA with morphine
Study: 33229930
Drug: Opioid group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid group: patient‐controlled analgesia (PCA) with morphine
Study: 34280012
Drug: GST-HG141 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST-HG141 (300 mg)
Study: 34280012
Drug: GST-HG141 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST-HG141 (50 mg)
Study: 34280012
Drug: GST-HG141 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST-HG141 (100 mg)
Study: 32334845
Drug: Biosimilar BE1040V
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosimilar BE1040V plus FOLFIRI-3 (5 mg/kg IV every 2 weeks for 1 year)
Study: 32334845
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug plus FOLFIRI-3 (dosage not specified, every 2 weeks for 1 year)
Study: 35157527
Drug: Salt loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt loading (3,900 mg sodium for 10 days)
Study: 34759933
Drug: Eptinezumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptinezumab (10 to 1000 mg, administered intravenously for up to 4 doses at 12-week intervals)
Study: 32102054
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (SB) supplementation at a dosage of 0.3 g·kg BM in gelatine capsules
Study: 33905287
Drug: Group Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Therapy for Improving Emotional Acceptance and Regulatory Skills in Adults with ADHD (GEARS)
Study: 32657198
Drug: Therapy Behavior
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy Behavior Scale (TBS) Version 2.2
Study: 33044437
Drug: Carbohydrate beverage
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate beverage (1.2 g·min‐1 glucose) after breakfast omission
Study: 33044437
Drug: Carbohydrate beverage
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate beverage (1.2 g·min‐1 glucose) after breakfast consumption
Study: 33290360
Drug: Notched music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Notched music therapy
Study: 33290360
Drug: Conventional music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional music therapy
Study: 34613379
Drug: Early physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physical therapy (PT)
Study: 32060567
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment combined with intravenous alteplase
Study: 32060567
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment as single treatment
Study: 32905673
Drug: Continuous high-flow
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-flow oxygen therapy with frequency of suctioning as the indicator of readiness for decannulation
Study: 32905673
Drug: 24-hour capping
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour capping trial plus intermittent high-flow oxygen therapy
Study: 34808142
Drug: R+L− stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: R+L− stimulation (tDCS over bilateral DLPFC)